Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.34 |
| ▸ | NPY4R | P50391 | 5/20 | 0.31 |
| ▸ | NPY1R | P25929 | 3/20 | 0.31 |
| ▸ | NPY2R | P49146 | 2/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.30 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.30 |
| ▸ | GNPAT | O15228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22790598 | 0.85 | NPY5R (0.36) | SIRT5NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL22788836 | 0.83 | FURIN (0.36) | SIRT5C3AR1 | |
| SCHEMBL21781921 | 0.81 | SIRT5 (0.37) | SIRT5NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL22788849 | 0.80 | C3AR1 (0.36) | SIRT5C3AR1 | |
| SCHEMBL22708835 | 0.77 | CACNA1B (0.45) | SIRT5NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL10441955 | 0.75 | C3AR1 (0.38) | SIRT5C3AR1 | |
| SCHEMBL15691795 | 0.75 | C3AR1 (0.38) | SIRT5C3AR1 | |
| SCHEMBL15315075 | 0.75 | C3AR1 (0.38) | SIRT5C3AR1 | |
| SCHEMBL21103049 | 0.75 | SIRT5 (0.38) | SIRT5NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL21781952 | 0.75 | GNPAT (0.35) | SIRT5GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020257235-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | SUTRO BIOPHARMA, INC. (US) | 2020-12-24 | — | — | WO | disclosed |